$PODD
INSULET CORP

2017 Q2 Form 10-Q Financial Statement

#000114519717000013 Filed on August 04, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $109.8M $87.33M
YoY Change 25.68% 44.23%
Cost Of Revenue $45.12M $36.87M
YoY Change 22.36% 22.76%
Gross Profit $64.64M $50.46M
YoY Change 28.11% 65.35%
Gross Profit Margin 58.89% 57.78%
Selling, General & Admin $49.97M $38.79M
YoY Change 28.81% 19.34%
% of Gross Profit 77.3% 76.88%
Research & Development $18.03M $12.95M
YoY Change 39.19% 7.32%
% of Gross Profit 27.89% 25.67%
Depreciation & Amortization $3.390M $3.430M
YoY Change -1.17% -6.79%
% of Gross Profit 5.24% 6.8%
Operating Expenses $68.00M $51.75M
YoY Change 31.41% 16.09%
Operating Profit -$3.358M -$1.288M
YoY Change 160.71% -90.84%
Interest Expense -$4.300M -$3.000M
YoY Change 43.33% -6.25%
% of Operating Profit
Other Income/Expense, Net -$4.308M -$2.998M
YoY Change 43.7% -6.11%
Pretax Income -$7.666M -$4.286M
YoY Change 78.86% -75.16%
Income Tax $101.0K $100.0K
% Of Pretax Income
Net Earnings -$7.767M -$4.198M
YoY Change 85.02% -72.8%
Net Earnings / Revenue -7.08% -4.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$134.5K -$73.43K
COMMON SHARES
Basic Shares Outstanding 57.92M shares 57.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $258.6M $111.3M
YoY Change 132.35% -23.29%
Cash & Equivalents $73.49M $75.66M
Short-Term Investments $185.1M $35.60M
Other Short-Term Assets $8.400M $6.800M
YoY Change 23.53% 100.0%
Inventory $33.96M $24.49M
Prepaid Expenses
Receivables $37.75M $38.70M
Other Receivables $0.00 $0.00
Total Short-Term Assets $338.7M $181.3M
YoY Change 86.85% -11.06%
LONG-TERM ASSETS
Property, Plant & Equipment $75.88M $41.13M
YoY Change 84.48% -2.16%
Goodwill $39.76M $39.76M
YoY Change -0.01% 5.93%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.559M $88.00K
YoY Change 1671.59% -98.12%
Total Long-Term Assets $120.6M $81.76M
YoY Change 47.49% -15.34%
TOTAL ASSETS
Total Short-Term Assets $338.7M $181.3M
Total Long-Term Assets $120.6M $81.76M
Total Assets $459.3M $263.0M
YoY Change 74.62% -12.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.24M $21.61M
YoY Change -43.33% 20.59%
Accrued Expenses $34.65M $29.94M
YoY Change 15.73% 13.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.300M
YoY Change -62.9%
Total Short-Term Liabilities $48.02M $55.18M
YoY Change -12.98% 4.74%
LONG-TERM LIABILITIES
Long-Term Debt $340.8M $175.7M
YoY Change 94.0% 2.01%
Other Long-Term Liabilities $5.748M $4.730M
YoY Change 21.52% 61.93%
Total Long-Term Liabilities $346.6M $180.4M
YoY Change 92.1% 3.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.02M $55.18M
Total Long-Term Liabilities $346.6M $180.4M
Total Liabilities $394.6M $235.6M
YoY Change 67.49% 2.37%
SHAREHOLDERS EQUITY
Retained Earnings -$698.2M -$668.2M
YoY Change 4.48% 10.4%
Common Stock $58.00K $57.00K
YoY Change 1.75% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.73M $27.44M
YoY Change
Total Liabilities & Shareholders Equity $459.3M $263.0M
YoY Change 74.62% -12.43%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$7.767M -$4.198M
YoY Change 85.02% -72.8%
Depreciation, Depletion And Amortization $3.390M $3.430M
YoY Change -1.17% -6.79%
Cash From Operating Activities $17.97M $3.680M
YoY Change 388.32% 365.82%
INVESTING ACTIVITIES
Capital Expenditures -$13.39M -$2.750M
YoY Change 386.91% 1000.0%
Acquisitions
YoY Change
Other Investing Activities -$8.590M -$34.49M
YoY Change -75.09%
Cash From Investing Activities -$21.98M -$37.24M
YoY Change -40.98% 14796.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.260M -2.410M
YoY Change -152.28% 141.0%
NET CHANGE
Cash From Operating Activities 17.97M 3.680M
Cash From Investing Activities -21.98M -37.24M
Cash From Financing Activities 1.260M -2.410M
Net Change In Cash -2.750M -35.97M
YoY Change -92.35% 7719.57%
FREE CASH FLOW
Cash From Operating Activities $17.97M $3.680M
Capital Expenditures -$13.39M -$2.750M
Free Cash Flow $31.36M $6.430M
YoY Change 387.71% 518.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58059598 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
dei Trading Symbol
TradingSymbol
PODD
CY2016Q2 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1007000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
2013000 USD
CY2017Q2 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1413000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
2827000 USD
CY2017Q2 podd Finited Lived Intangible Assets Excluding Software In Process Of Development Net
FinitedLivedIntangibleAssetsExcludingSoftwareInProcessOfDevelopmentNet
1667000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-7408000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1097000 USD
CY2017Q2 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
5486000 USD
CY2017Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34648000 USD
podd Interestand Other Expense Total
InterestandOtherExpenseTotal
10895000 USD
CY2017Q2 podd Number Of Financial Institution
NumberOfFinancialInstitution
1 location
CY2017Q2 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2016 podd Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities
PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities
0.16
podd Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities
PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities
0.16
podd Return Period
ReturnPeriod
P45D
podd Return Period Canada
ReturnPeriodCanada
P90D
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
41228000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13160000 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12243000 USD
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2886000 USD
CY2017Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
741000 USD
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
31714000 USD
CY2017Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
40410000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28803000 USD
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37753000 USD
CY2016Q2 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
3015000 USD
podd Interestand Other Expense Total
InterestandOtherExpenseTotal
6005000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41228000 USD
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34648000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6753000 USD
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6172000 USD
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
21999000 USD
CY2017Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
18746000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39000000 USD
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45200000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-726000 USD
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-529000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P2Y6M
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
744243000 USD
CY2017Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
763364000 USD
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5514000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10785000 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7531000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14655000 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2911000 USD
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2657000 USD
CY2016Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1727000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3429000 USD
CY2017Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3573000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7078000 USD
CY2016Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
281000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
563000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
990000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2017Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
500000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3992000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8067000 USD
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 USD
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8918507 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11914219 shares
CY2016Q4 us-gaap Assets
Assets
456647000 USD
CY2017Q2 us-gaap Assets
Assets
459327000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
369960000 USD
CY2017Q2 us-gaap Assets Current
AssetsCurrent
338745000 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
161396000 USD
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
185117000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
207000 USD
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
274000 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
161603000 USD
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
185391000 USD
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
161396000 USD
CY2017Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
185117000 USD
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0 USD
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0 USD
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2100000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122672000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75661000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137174000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73488000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-47011000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-63686000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
2000000 USD
CY2017Q2 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57457967 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58044088 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57457967 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58044088 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
57000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
58000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4187000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16268000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7638000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17547000 USD
CY2016Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36873000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
74035000 USD
CY2017Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45117000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
87432000 USD
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
69684000 USD
CY2017Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
62606000 USD
CY2016Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
9632000 USD
CY2017Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
8642000 USD
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
1900000 USD
CY2017Q2 us-gaap Deferred Revenue
DeferredRevenue
2000000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1309000 USD
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1127000 USD
CY2016Q2 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
0 USD
us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
100000 USD
CY2017Q2 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
0 USD
us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6845000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6707000 USD
CY2016Q2 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
0.00
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
-0.03
CY2017Q2 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
0.00
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
0.00
CY2016Q2 us-gaap Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense
DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense
400000 USD
us-gaap Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense
DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense
700000 USD
CY2017Q2 us-gaap Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense
DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense
0 USD
us-gaap Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense
DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense
0 USD
us-gaap Discontinued Operation Period Of Continuing Involvement After Disposal
DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
P0Y6M0D
CY2016Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
408000 USD
CY2017Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
205000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
257000 USD
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
51470000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4017000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4546000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
706000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
463000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
106000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
392000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6058000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
6223000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7932000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15842000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2041000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3386000 USD
CY2016Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2017Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30581000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20493000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39604000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
39677000 USD
CY2017Q2 us-gaap Goodwill
Goodwill
39759000 USD
CY2016Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2016Q2 us-gaap Gross Profit
GrossProfit
50457000 USD
us-gaap Gross Profit
GrossProfit
94508000 USD
CY2017Q2 us-gaap Gross Profit
GrossProfit
64639000 USD
us-gaap Gross Profit
GrossProfit
124037000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4286000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14911000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7666000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17547000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-4351000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-15040000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7767000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-17744000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.08
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.26
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.13
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.31
CY2016Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
153000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1639000 USD
CY2017Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
129000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
101000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3672000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9630000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1020000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
44000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13099000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1527000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
765000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
477000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2205000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1662000 USD
CY2016Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3127000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1911000 USD
CY2017Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2501000 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
15681000 USD
CY2017Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4796000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
9803000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
17922000 USD
CY2017Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11704000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
35514000 USD
CY2017Q2 us-gaap Inventory Net
InventoryNet
33956000 USD
CY2017Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
19751000 USD
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1200000 USD
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1400000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
393497000 USD
CY2017Q2 us-gaap Liabilities
Liabilities
394602000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
456647000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
459327000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55697000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
48018000 USD
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
332768000 USD
CY2017Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
340836000 USD
CY2015Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
400000 USD
CY2016Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
300000 USD
us-gaap Loss Contingency Claims Dismissed Number
LossContingencyClaimsDismissedNumber
2 LegalMatter
CY2015Q2 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3 LegalMatter
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4592000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4194000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35788000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64266000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6836000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3871000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4198000 USD
us-gaap Net Income Loss
NetIncomeLoss
-16679000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-7767000 USD
us-gaap Net Income Loss
NetIncomeLoss
-17744000 USD
CY2016Q4 us-gaap Noncurrent Assets
NoncurrentAssets
44969000 USD
CY2017Q2 us-gaap Noncurrent Assets
NoncurrentAssets
76011000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2998000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5924000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4308000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8881000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
51745000 USD
us-gaap Operating Expenses
OperatingExpenses
103495000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
67997000 USD
us-gaap Operating Expenses
OperatingExpenses
132703000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1288000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8987000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3358000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8666000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
13688000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2684000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Rolling Year Four
OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour
2383000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Rolling Year Three
OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree
2402000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Rolling Year Two
OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo
2681000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2131000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1407000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7948000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7395000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
216000 USD
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1559000 USD
CY2016Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
403000 USD
CY2017Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
186000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
264000 USD
CY2016Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
411000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
129000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
197000 USD
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000 USD
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-57000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-67000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5032000 USD
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5748000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
129000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
299000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
488000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
922000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
132000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
374000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2610000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3428000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
35597000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
93383000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5905000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39068000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5406000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5400000 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7073000 USD
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8431000 USD
us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
5714000 USD
us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1490000 USD
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7891000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
53855 shares
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
68185000 USD
CY2015Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4152000 USD
CY2016Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4160000 USD
CY2016Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4294000 USD
CY2016Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4388000 USD
CY2017Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4562000 USD
CY2017Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4817000 USD
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1642000 USD
CY2017Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1594000 USD
CY2016Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
2746000 USD
CY2017Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3223000 USD
CY2016Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
978000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1997000 USD
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
880000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1212000 USD
CY2016Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1112000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
2139000 USD
CY2017Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1135000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1641000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44753000 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75878000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1074000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
722000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3472000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
269000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12953000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25942000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18029000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35529000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1200000 USD
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1200000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-680424000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-698168000 USD
CY2016Q2 us-gaap Revenues
Revenues
87330000 USD
us-gaap Revenues
Revenues
168543000 USD
CY2017Q2 us-gaap Revenues
Revenues
109756000 USD
us-gaap Revenues
Revenues
211469000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
87330000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
168543000 USD
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
109756000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
211469000 USD
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22950000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
46972000 USD
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
29475000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
57570000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10784000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
487402 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.16
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.27
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
59948000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3441303 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3582149 shares
us-gaap Share Based Compensation
ShareBasedCompensation
14655000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3334992 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1734065 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.57
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
56274000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3330380 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
24.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
33.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.75
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
31475000 USD
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2016Q2 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
700000 USD
us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
1700000 USD
CY2017Q2 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
900000 USD
us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
2200000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
292701 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
63150000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
64725000 USD
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57196000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57113000 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57977000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57836000 shares
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Nature of the Business </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Insulet Corporation, the "Company," is primarily engaged in the development, manufacturing and sale of its proprietary Omnipod Insulin Management System (&#8220;Omnipod System&#8221;), an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager ("PDM"). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:Arial;font-size:10pt;">42</font><font style="font-family:Arial;font-size:10pt;"> inches of tubing. In contrast, the Omnipod System features only two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Company believes that the Omnipod System&#8217;s unique proprietary design and features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience, and ease. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial sales of the Omnipod System began in the United States in 2005. The Company sells the Omnipod System in the United States through direct sales to customers or through its distribution partners. The Omnipod System is currently available in multiple countries in Europe, as well as in Canada and Israel. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">The Company announced on July 20, 2017 its plans to assume, on July 1, 2018, the distribution, sales, marketing, training and support activities of its Omnipod System across Europe following the expiration of its global distribution agreement with Ypsomed Distribution AG ("Ypsomed') on June 30, 2018. Until the expiration of the agreement, Ypsomed will remain the distributor of the Company's Omnipod products in Europe. The Company will be required to pay to Ypsomed a per unit fee for direct sales over the 12 month period following the expiration of the global distribution agreement of its Omnipod device to former customers of Ypsomed, as defined in the distribution agreement. The Company will recognize a liability for this fee as it sells its Omnipod device to these customers during the twelve-month period beginning July 1, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to using the Omnipod System for insulin delivery, the Company also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas.</font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in </font><font style="font-family:Arial;font-size:10pt;">June 2011</font><font style="font-family:Arial;font-size:10pt;">. Through Neighborhood Diabetes, the Company provided customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and had the ability to process claims as either durable medical equipment or through pharmacy benefits. In February 2016, the Company sold Neighborhood Diabetes to Liberty Medical LLC ("Liberty Medical"). Additional information regarding the disposition and treatment of the Neighborhood Diabetes business as discontinued operations is provided in Note </font><font style="font-family:Arial;font-size:10pt;">3</font><font style="font-family:Arial;font-size:10pt;"> to these consolidated financial statements.</font></div></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification of Prior Period Balances</font></div><div style="line-height:120%;padding-top:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation including the reclassification of capitalized internal-use software costs from&#160;property and equipment to&#160;other intangible assets for the year ended December 31, 2016 upon adoption of Accounting Standards Update ("ASU")&#160;2016-19,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Technical Corrections and Improvements</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense; the fair value of intangible assets acquired in businesses combinations; the valuation of inventory; the fair value of reporting units used to calculate the potential impairment of goodwill; the valuation of deferred revenue; the calculation of gains and losses, if any, on the retirement or conversion of convertible debt; the estimated useful lives of property and equipment and intangible assets; the amount of internal use software development costs that qualify for capitalization; the estimated amount, if any, of accrued contingent liabilities as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001145197-17-000013-index-headers.html Edgar Link pending
0001145197-17-000013-index.html Edgar Link pending
0001145197-17-000013.txt Edgar Link pending
0001145197-17-000013-xbrl.zip Edgar Link pending
a2017planrsuformemployee_e.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
podd-20170630.xml Edgar Link completed
podd-20170630.xsd Edgar Link pending
podd-20170630_cal.xml Edgar Link unprocessable
podd-20170630_def.xml Edgar Link unprocessable
podd-20170630_lab.xml Edgar Link unprocessable
podd-20170630_pre.xml Edgar Link unprocessable
podd-2017x06x30_10q.htm Edgar Link pending
podd-exx102_20170630x10q.htm Edgar Link pending
podd-exx103_20170630x10q.htm Edgar Link pending
podd-exx104_20170630x10q.htm Edgar Link pending
podd-exx105_20170630x10q.htm Edgar Link pending
podd-exx311_20170630x10q.htm Edgar Link pending
podd-exx312_20170630x10q.htm Edgar Link pending
podd-exx321_20170630x10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending